Instrument Inactif

Communiqués Ra Pharmaceuticals, Inc.

Actions

US74933V1089

Recherche biotechnologique et médicale

Communiqués

02/04/20	RA PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
31/03/20	RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	AQ
16/03/20	RA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
02/03/20	Ra Pharmaceuticals : Supports 13th Annual Rare Disease Day and Joins Global Movement to Raise Awareness for Rare Diseases	AQ
28/02/20	RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	AQ
28/02/20	Ra Pharmaceuticals : Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases	BU
27/02/20	Ra Pharmaceuticals : Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update	BU
27/02/20	RA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
18/02/20	Ra Pharmaceuticals : Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology	BU
22/01/20	Ra Pharmaceuticals : Announces Clearance of IND Application for the HEALEY ALS Platform Trial	BU
18/12/19	RA PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	AQ
04/12/19	Ra Pharmaceuticals : Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM	BU
25/11/19	RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	AQ
07/11/19	Ra Pharmaceuticals : Reports Third Quarter 2019 Financial Results and Provides Corporate Update	BU
15/10/19	RA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ra Pharmaceuticals, Inc. - RARX	BU
10/10/19	Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on Behalf of Ra Pharma Shareholders and Encourages Ra Pharma Investors to Contact the Firm	PR
10/10/19	Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale of Ra Pharmaceuticals; Is $48 a Fair Price?	PR
10/10/19	UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases	BU
02/10/19	Ra Pharmaceuticals : Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG	BU
18/09/19	Ra Pharmaceuticals : Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General	BU
04/09/19	Ra Pharmaceuticals : Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis	BU
21/08/19	Ra Pharmaceuticals : Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck	BU
07/08/19	Ra Pharmaceuticals : Reports Second Quarter 2019 Financial Results and Provides Corporate Update	BU
26/07/19	Ra Pharmaceuticals : Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	BU
24/07/19	Ra Pharmaceuticals : Announces Pricing of Public Offering of Common Stock	BU